{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:03:55Z","timestamp":1774699435226,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejso.2026.111508","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:46:31Z","timestamp":1772005591000},"page":"111508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Asako","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5001","authenticated-orcid":false,"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Chishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111508_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.111508_bib2","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1200\/JCO.2005.11.124","article-title":"Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy","volume":"23","author":"Gonzalez-Angulo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.bjc.6605769","article-title":"Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy","volume":"103","author":"Tanioka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2026.111508_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-015-3533-x","article-title":"Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy","volume":"153","author":"Chaudry","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2026.111508_bib5","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib6","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","article-title":"Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy","volume":"45","author":"Asaoka","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1245\/s10434-024-15583-4","article-title":"Impact of presenting stage on overall survival in patients treated with neoadjuvant chemotherapy for triple negative breast cancer","volume":"31","author":"Carroll","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.111508_bib9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib10","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/cncr.31518","article-title":"Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis","volume":"124","author":"Valachis","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2026.111508_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-022-00380-7","article-title":"Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab","volume":"8","author":"Ferraro","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ejso.2026.111508_bib12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.14740\/wjon2662","article-title":"Organ-specific clinicopathological features that are associated with post-relapse survival of metastatic breast cancer in Japanese women: a multicenter cohort study","volume":"17","author":"Koyama","year":"2026","journal-title":"World J Oncol"},{"key":"10.1016\/j.ejso.2026.111508_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13058-025-02123-5","article-title":"Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort study","volume":"27","author":"Koyama","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejso.2026.111508_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111508_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326001277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326001277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:35:39Z","timestamp":1774697739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326001277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0748798326001277"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111508","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111508"}}